



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Product Information


Description:	Recombinant human CD200RI (cluster of differentiation 200 receptor 1), encompassing extracellular amino acids 29-265. This construct contains a C-terminal Fc domain from human IgG1 followed by an Avi-Tag™. This protein was affinity purified.
Background:	CD200RI (cluster of differentiation 200 receptor 1), also known as OX-2R, is a transmembrane glycoprotein. It is found in cells of the myeloid and lymphoid lineage, such as CD4 ⁺ cells. It acts as immune inhibitory receptor, but contrary to other proteins with the same function, it does exhibit an ITIM (tyrosine-based inhibitory motif) domain. When bound to CD200 it contributes to the formation of an immunosuppressive TEM (tumor microenvironment), via a Dok1 (docking protein 1), Dok2 and RasGAP dependent mechanism, leading to T cell responses inhibition, NK cell cytotoxicity decrease, potentiation of Treg cell expansion and decrease of other immune responses to cancer cells. In addition to cancer, CD200 is linked to auto-immune disorders, inflammation, infection, graft survival and cancer. Samalizumab, an anti-CD200 monoclonal antibody, has resulted in positive outcomes when used in patients suffering from CLL (chronic lymphocytic leukemia) and MM (multiple myeloma). Inhibition of the interaction between CD200 and CD200RI may thus be beneficial as a new therapy approach in CD200-related diseases.
Species:	Human
Construct:	CD200RI (29-265-Fc(IgG1)-Avi)-(Biotin)
Concentration:	1.39 mg/ml
Expression System:	HEK293
Purity:	≥90%
Format:	Aqueous buffer solution.
Formulated In:	8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
MW:	55 kDa + glycans
Glycosylation:	This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank Accession:	NM_138806.4
Label:	This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%.
Stability:	At least 6 months at -80°C.
Storage:	-80°C
Instructions for Use:	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Applications:	Useful for binding assays.

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



Biotin-Avidin Pulldown



1. Beads
2. Flow Thru
3. Control
4. Standards

* Avidin from beads.